Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer:: Variables associated with benign and malignant etiology

被引:36
作者
Karam, Maroun [1 ]
Roberts-Klein, Shayna [1 ]
Shet, Narendra [2 ]
Chang, Johanna [2 ]
Feustel, Paul [3 ]
机构
[1] Albany Med Coll, Dept Radiol, Nucl Med Sect, Albany, NY 12208 USA
[2] Albany Med Coll, Neuropharmacol Radiol Dept, Albany, NY 12208 USA
[3] Albany Med Coll, Dept Radiol, Albany, NY 12208 USA
关键词
F-18-FDG PET scan; bilateral hilar foci; benign;
D O I
10.2967/jnumed.107.048983
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];
摘要
Bilateral hilar F-18-FDG-avid foci are often noted on PET studies of patients without lung cancer. This finding may lead to diagnostic uncertainty about the presence of metastatic disease. Our objective was to evaluate features of these foci associated with benign or malignant etiology. Methods: We performed a retrospective study of patients with cancer with bilateral hilar foci on 1 or 2 sequential F-18-FDG PET studies between 2002 and 2006. Patients with lung cancer, sarcoidosis, or anthracosis/silicosis were excluded. Variables evaluated were maximum standard uptake values (SUV max), purity (absence of F-18-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary tumor, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time. The gold standard was histologic diagnosis or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo). Results: Fifty-one patients with the finding of bilateral hilar F-18-FDG-avid foci underwent a staging-only PET study; 52 scans from an additional set of patients demonstrated this abnormality on at least 1 of 2 sequential studies, the first of which was performed for staging. On univariate analysis, variables associated with malignancy were SUV max (6.6 +/- 4.1 vs. 3.5 +/- 1.0 for benign, P < 0.001; t test); impurity (P < 0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P = 0.027); and change in uptake between scans 1 and 2 (change in SUV = 2.7 +/- 2.1 vs. 0.73 +/- 1.1 for benign, P < 0.01; t test). Variables associated with benign etiology were: symmetry (difference between left and right sides = 0.57 +/- 0.54 for benign vs. 1.8 +/- 1.7 for malignant, P < 0.01), purity, and colorectal primary (75% of colorectal were benign vs. 34% of breast, 49% of lymphoma, and 37% of other, P = 0.030; chi(2) test). After multivariate analysis, SUV max and purity were found to be independent predictors, with the odds of malignancy increasing by 1.54 (95% confidence interval, 1.16-2.05) for each unit increase in SUV and decreasing by 0.08 (95% confidence interval, 0.03-0.22) if pure. Conclusion: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a benign etiology.
引用
收藏
页码:1429 / 1436
页数:8
相关论文
共 16 条
[1]
Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer [J].
Alongi, Filippo ;
Ragusa, Pietro ;
Montemaggi, Paolo ;
Bona, Cristina Maria .
TUMORI JOURNAL, 2006, 92 (04) :327-333
[2]
Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer [J].
Bryant, Ayesha S. ;
Cerfolio, Robert J. ;
Klemm, Katrin M. ;
Ojha, Buddhiwardhan .
ANNALS OF THORACIC SURGERY, 2006, 82 (02) :417-423
[3]
18F-FDG PET in malignant lymphoma:: significance of positive findings [J].
Castellucci, P ;
Zinzani, P ;
Pourdehnad, M ;
Alinari, L ;
Nanni, C ;
Farsad, M ;
Battista, G ;
Tani, M ;
Stefoni, V ;
Canini, R ;
Monetti, N ;
Rubello, D ;
Alavi, A ;
Franchi, R ;
Fanti, S .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (07) :749-756
[4]
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer - A meta-analysis [J].
Gould, MK ;
Kuschner, WG ;
Rydzak, CE ;
Maclean, CC ;
Demas, AN ;
Shigemitsu, H ;
Chan, JK ;
Owens, DK .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (11) :879-892
[5]
Size of metastatic and nonmetastatic mediastinal lymph nodes in non-small cell lung cancer [J].
Ikeda, Koei ;
Nomori, Hiroaki ;
Mori, Takeshi ;
Kobayashi, Hironori ;
Iwatani, Kazunori ;
Yoshimoto, Kentaro .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) :949-952
[6]
Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country -: Diagnostic efficacy in 674 patients [J].
Kim, Yoon Kyung ;
Lee, Kyung Soo ;
Kim, Byung-Tae ;
Choi, Joon Young ;
Kim, Hojoong ;
Kwon, O. Jung ;
Shim, Young Mog ;
Yi, Chin A. ;
Kim, Ha Young ;
Chung, Myung Jin .
CANCER, 2007, 109 (06) :1068-1077
[7]
Kirschner P A, 1996, Chest Surg Clin N Am, V6, P1
[8]
The role of thoracoscopy in the management of lung cancer [J].
Lin, J ;
Iannettoni, MD .
SURGICAL ONCOLOGY-OXFORD, 2003, 12 (03) :195-200
[9]
Endobronchial and endoscopic ultrasound-guided real-time fine-needle aspiration for mediastinal staging [J].
Rintoul, RC ;
Skwarski, KM ;
Murchison, JT ;
Wallace, WA ;
Walker, WS ;
Penman, ID .
EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (03) :416-421
[10]
Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods in the thoracic and extrathoracic staging of non-small cell lung cancer [J].
Rodriguez Fernandez, Antonio ;
Gomez Rio, Manuel ;
Llamas Elvira, Jose Manuel ;
Sanchez-Palencia Ramos, Abel ;
Bellon Guardia, Maria ;
Ramos Font, Carlos ;
Torne Poyatos, Pablo ;
Pedraza Muriel, Vicente .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (01) :32-39